Balyasny Asset Management
AARD

Balyasny Asset Management’s Aardvark Therapeutics AARD Stock Holding History

Balyasny Asset Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,817
Closed -$181K – 3685
2025
Q4 		$181K Buy
+13,817
New +$172K ﹤0.01% 2902
2025
Q2 		– Sell
-35,435
Closed -$266K – 3486
2025
Q1 		$266K Buy
+35,435
New +$398K ﹤0.01% 2494

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management's AARD Position: Q1 2026 in Review

Balyasny Asset Management sold out of Aardvark Therapeutics (AARD) in Q1 2026, closing a stake of 13,817 shares — an estimated $181K sold.

Balyasny Asset Management first reported a position in AARD in Q1 2025 and held it in 2 quarters. The position peaked at $266K in Q1 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Balyasny Asset Management reported no remaining Aardvark Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 13,817 Aardvark Therapeutics shares in Q1 2026, an estimated $181K.
  • Balyasny Asset Management first reported a position in Aardvark Therapeutics in Q1 2025 and held it in 2 quarters.
  • Balyasny Asset Management's Aardvark Therapeutics position peaked at $266K in Q1 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.